Positional Cloning and Electronic Signature or e-sig

Side effects and complications in the use of drugs: more - blood flow, thinning hair possible - headache, nausea, peripheral edema (6-7% of cases), at least - vomiting, dyspepsia, weight gain, myalgia, arthralgia, anorexia, rash on the skin, less than 2% of patients - from vaginal bleeding, constipation, dizziness, sweating, shortness of breath, thrombophlebitis. Indications for use drugs: widespread breast cancer in postmenopausal women, early stage breast cancer (adjuvant) in postmenopausal women with a positive test here in sensitivity to estrogen, which can not use tamoxifen because of the high risk of thromboembolism or endometrial abnormalities. Pharmacotherapeutic group: L02BG04 - Hormone antagonists and similar facilities. Contraindications to bogotify use of drugs: late reproductive bogotify pregnancy, lactation, severe renal disorders (creatinine clearance <20 ml / min), hepatic failure, hypersensitivity to the drug. Method of production of drugs: Table., Coated tablets, 5.2 mg to number 30 in blisters. Dosing and Administration of drugs: for adults, including elderly persons - 1 1 p internally mg / day. Antineoplastic and immunomodulating agents. The main effect of pharmaco-therapeutic effects of drugs: an irreversible inhibitor of steroid aromatase, Immunoglobulin structure is similar to natural substances androstendionu; acts by blocking the formation of estrogen by inhibiting aromatase, the bogotify of action is due to irreversible binding to the active fragment of the enzyme, leading to inactivation Surgery the latter; in postmenopausal 90 %) досягається при застосуванні дози 10 – 25 мг; bogotify пацієнток у постменопаузі з діагнозом рак молочної залози, які отримували 25 мг щоденно, загальний рівень ароматази знижувався на" onmouseout="this.style.backgroundColor='fff'"reduces the concentration of estrogen in the serum, starting with a dose of 5 mg, the maximum reduction (> 90%) achieved in the application Inflammatory Breast Cancer of 10 - 25 mg in postmenopausal patients diagnosed with breast cancer who received 25 mg daily, decreasing bogotify overall level of aromatase 98%; does not have estrogenic activity and prohestohennoyi; revealed only minor androgenic activity (at high doses), with the introduction of multiple doses throughout the day did not influence the synthesis of cortisol and Ventilation/perfusion Scan in the adrenal glands, confirming the selectivity of action, there's no need for replacement therapy Glucocorticoid and mineralocorticoid hormone, progestin increase in levels of follicle stimulating hormone and serum was observed even at low doses, this effect is developed on the basis of feedback at the pituitary. Pharmacotherapeutic group: L03AA10 - colony factors. here mg, 100 mg № 20, № 60, Mr Oil for injections of 3 ml (300 mg) in the amp. Enzyme inhibitors. L02BG06 - enzyme inhibitors. Preparations of drugs: Table., Sugar-coated tablets, 25 mg № 30.